28 completed, 9 recruiting, 6 unknown, 2 active not recruiting. 15 Phase 2, 10 Phase 1, 3 Not applicable, 3 Phase 3, 2 Phase 4.
Follow Lymphangiomyoma: new trials by email Literature Review of Lymphangiomyoma trials Research Report on Lymphangiomyoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM) Imatimib Mesylate, Placebo - Lymphangioleiomyomatosis (LAM), Lymphangioleiomyomatosis | Phase 1 | Recruiting | Columbia University | 20 | 2025-10-20 | 2026-01-21 |
| Role of Extracellular Vesicles as Biomarkers of Pulmonary Involvement in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex Pulmonary Function Test, Analysis of Extracellular Vesicles - Lymphangioleiomyomatosis (LAM), Extracellular Vesicles; Generation and Function | Recruiting | University of Milan | 80 | 2025-04-16 | 2025-12-26 | |
| The Genotype and Phenotype of Lymphangioleiomyomatosis Sporadic Lymphangioleiomyomatosis, TSC-associated Lymphangioleiomyomatosis | Recruiting | National Taiwan University Hospital | 100 | 2024-05-10 | 2024-05-09 | |
| Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) Tuberous Sclerosis Complex, Lymphangioleiomyomatosis | Recruiting | David M. Ritter | 300 | 2023-07-01 | 2026-01-23 | |
| Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases Breath test using the Compact PTR-TOF-MS, Portable cardiac monitor "CardioQvark", Assessment of arterial stiffness using the VaSera VS-1500N - Chronic Respiratory Diseases, Cystic Fibrosis | Enrolling by invitation | I.M. Sechenov First Moscow State Medical University | 400 | 2023-01-30 | 2024-07-30 | |
| Lymphangioleiomyomatosis, a Study on Cathepsin K 24h urine, urine sample - Lymphangioleiomyomatosis, Tuberous Sclerosis Complex | Completed | University Hospital, Tours | 19 | 2022-05-31 | 2023-03-29 | |
| Characterizing LAM With 11C-Choline PET/CT 11C-Choline - Lymphangioleiomyomatosis | Early Phase 1 | Unknown | Peking Union Medical College Hospital | 50 | 2021-11-01 | 2021-10-21 |
| Effect of Loratadine in Lymphangioleiomyomatosis Loratadine, Placebo 10mg/day added to rapamycin for 12 months - Lymphangioleiomyomatosis | Phase 2 | Unknown | Institut d'Investigació Biomèdica de Bellvitge | 62 | 2021-11-01 | 2022-01-27 |
| Feasibility of [11C]Acetate-PET in LAM and TSC [11C]acetate - Lymphangioleiomyomatosis, Tuberous Sclerosis Complex | Phase 1 / Phase 2 | Active not recruiting | Brigham and Women's Hospital | 7 | 2021-08-30 | 2026-01-21 |
| Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis LAM patients underwent PSG - Lymphangioleiomyomatosis, Sleep Disorder | Not applicable | Unknown | dr. Stefano Nava | 15 | 2020-06-30 | 2021-03-18 |
| Benefits of Pulmonary Rehabilitation in Patients With Severe Lymphangioleiomyomatosis (LAM) Pulmonary Rehabilitation - Lymphangioleiomyomatosis, LAM | Completed | Schön Klinik Berchtesgadener Land | 58 | 2019-12-03 | 2020-01-21 | |
| Molecular Characterization of Perivascular Epithelioid Cell Tumors Perivascular Epithelioid Cell Tumor, Malignant | Unknown | University Hospital, Strasbourg, France | 100 | 2019-12-01 | 2022-11-15 | |
| Glutamine PET Imaging in LAM Glutamine - Lymphangioleiomyomatosis (LAM) | Phase 1 | Completed | Vanderbilt University Medical Center | 5 | 2019-10-18 | 2021-08-11 |
| Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex. Everolimus - Renal Angiomyolipoma | Phase 4 | Completed | Novartis Pharmaceuticals | 40 | 2018-11-09 | 2021-09-09 |
| Biomarkers for Tuberous Sclerosis Complex (BioTuScCom) Hypomelanotic Macules, Facial Angiofibroma | Terminated | CENTOGENE GmbH Rostock | 20 | 2018-08-01 | 2023-02-10 | |
| Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial Sirolimus, Resveratrol - Lymphangioleiomyomatosis | Phase 2 | Completed | University of Cincinnati | 25 | 2018-03-31 | 2023-02-01 |
| LAM Pilot Study With Imatinib Mesylate Imatinib Mesylate 400Mg Capsule, Placebo - Capsule - Lymphangioleiomyomatosis | Phase 1 / Phase 2 | Completed | Medical University of South Carolina | 18 | 2018-01-23 | 2020-06-16 |
| Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial Sirolimus - LAM, Lymphangioleiomyomatosis | Phase 3 | Active not recruiting | University of Cincinnati | 60 | 2018-01-01 | 2024-12-24 |
| Discovery of Sirolimus Sensitive Biomarkers in Blood Sirolimus 2mg - Lymphangioleiomyomatosis | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 33 | 2017-12-04 | 2026-02-18 |
| A National Registry on Chinese Patients With Lymphangioleiomyomatosis Pulmonary Function | Unknown | Peking Union Medical College Hospital | 1500 | 2017-01-01 | 2021-09-24 |
Showing 20 of 48. Sign in to see all of them.
Lymphangioleiomyomatosis (48) · Tuberous Sclerosis (16) · Angiomyolipoma (5) · Lung Diseases (3) · Ascites (2) · Asthma (2) · Astrocytoma (2) · Hereditary Sensory and Autonomic Neuropathies (2) · Pneumothorax (2) · Pulmonary Disease, Chronic Obstructive (2) · Acute Lung Injury (1) · Alveolitis, Extrinsic Allergic (1) · Breast Neoplasms (1) · Bronchiectasis (1)
Hemic and Lymphatic Diseases (48) · Immune System Diseases (48) · Immunoproliferative Disorders (48) · Lymphatic Diseases (48) · Lymphoproliferative Disorders (48) · Neoplasm, Lymphatic Tissue (48) · Neoplasms by Histologic Type (48) · Neoplasms, Connective and Soft Tissue (48) · Neoplasms (47) · Perivascular Epithelioid Cell Neoplasms (47) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (19) · Genetic Diseases, Inborn (18) · Nervous System Diseases (18) · Heredodegenerative Disorders, Nervous System (17)
Sirolimus (10) · Everolimus (6) · Imatinib Mesylate (2) · Bevacizumab (1) · Celecoxib (1) · Cetuximab (1) · Disulfides (1) · Doxycycline (1) · Genetic Testing (1) · Glutamine (1) · Hydroxychloroquine (1) · Immunoglobulin G (1) · Letrozole (1) · Loratadine (1) · Octreotide (1)
National Heart, Lung, and Blood Institute (NHLBI) (8) · University of Cincinnati (5) · Brigham and Women's Hospital (3) · Novartis Pharmaceuticals (3) · Children's Hospital Medical Center, Cincinnati (2) · Peking Union Medical College Hospital (2) · CENTOGENE GmbH Rostock (1) · Cardiff University (1) · Columbia University (1) · David M. Ritter (1) · Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires (1) · I.M. Sechenov First Moscow State Medical University (1) · IRCCS Multimedica (1) · InCor Heart Institute (1) · Institut d'Investigació Biomèdica de Bellvitge (1)
United States (27) · France (6) · Italy (5) · Canada (3) · China (3) · United Kingdom (3) · Brazil (2) · Germany (2) · Japan (2) · Russia (2) · Spain (2) · Albania (1) · Egypt (1) · Georgia (1) · India (1)
Joel Moss, M.D. (4) · Francis X McCormack, MD (3) · Frank McCormack, MD (2) · Vincent Cottin, MD (2) · Angelo M Taveira-DaSilva, M.D. (1) · Carlos RR Carvalho, PhD (1) · Carlos Roberto Ribeiro Carvalho, MD, PhD (1) · Carmen P Priolo, MD PhD (1) · Christopher Meinberg (1) · David J Kwiatkowski, MD PhD (1) · David M Ritter, MD, PhD (1) · Elizabeth P Henske, MD (1) · Fang Li, MD (1) · Francis X. McCormack, M.D. (1)
PMID 21410393, PMID 12172553, PMID 18184959, PMID 21180274, PMID 21482669, PMID 21525172, PMID 24159565, PMID 24556663, PMID 24591665, PMID 25979023, PMID 26113676, PMID 26156073, PMID 26799509, PMID 26917604, PMID 28192114, PMID 28570161, PMID 29023494, PMID 30053159, PMID 30144422, PMID 30192751, PMID 30291925, PMID 30846465, PMID 31299246, PMID 32060062, PMID 32962746, PMID 33549601, PMID 36642366, PMID 36801466, PMID 36927115, PMID 36930738, PMID 37311055, PMID 39148107, PMID 39489895, PMID 41389341
1ZIAHL002541-21 (1), 2008 (1), R21CA103486 (1), R34HL138235 (1), U01HL058440 (1), U01HL131755 (1), U54HL127672 (1), U54RR019498 (1)